REG - Syncona Limited - Director Declaration

SynconaAnnouncement

22/06/2022 17:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220622:nRSV8659Pa&default-theme=true

RNS Number : 8659P  Syncona Limited  22 June 2022

Syncona Limited (the "Company")

Director Declaration

 

22 June 2022

In accordance with the requirements of the Listing Rule 9.6.14R, the Company
advises the following change to directorships in other publicly quoted
companies, held by the following member of the Board:

Virginia Holmes was appointed to Murray International Trust PLC on 22 June
2022.

Enquiries

Syncona Ltd

Andrew Cossar

Tel: +44 (0) 20 3981 7940

 

Citco Fund Services (Guernsey) Limited

Company Secretary

Tel: +44 (0) 1481 758200

 

About Syncona:

Syncona is a leading FTSE250 healthcare company whose purpose is to invest to
extend and enhance human life by founding and building a portfolio of global
leaders in life science to deliver transformational treatments to patients in
areas of high unmet need.

Our strategy is to found, build and fund companies around exceptional science
to create a diversified portfolio of 15-20 globally leading healthcare
businesses for the benefit of all our stakeholders. We focus on developing
treatments for patients by working in close partnership with world-class
academic founders and management teams. Our balance sheet underpins our
strategy enabling us to take a long-term view as we look to improve the lives
of patients with no or poor treatment options, build sustainable life science
companies and deliver strong risk-adjusted returns to shareholders.

Copies of this press release, a company results presentation, and other
corporate information can be found on the company website
at: www.synconaltd.com (http://www.synconaltd.com/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RDNQLLFLLQLLBBB